Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475627 | 0.76 | CES2 (0.44) | ALDH1A1 | |
| SCHEMBL898886 | 0.76 | — | — | |
| SCHEMBL28863906 | 0.75 | KMT2A (0.38) | ALDH1A1TDP1 | |
| SCHEMBL28153137 | 0.75 | ALDH1A1 (0.32) | ALDH1A1TSHRCYP2C9 | |
| SCHEMBL28837678 | 0.74 | — | — | |
| SCHEMBL59206 | 0.74 | — | — | |
| SCHEMBL6364296 | 0.73 | ALDH1A1 (0.32) | ALDH1A1TSHRCYP2C9 | |
| SCHEMBL9184100 | 0.73 | HTT (0.34) | ALDH1A1TSHR | |
| SCHEMBL31187561 | 0.72 | — | — | |
| SCHEMBL31489164 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9466827-B2 | Secondary battery | NEC CORPORATION (JP) | 2016-10-11 | — | — | US | claimed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-9466827-B2 | Secondary battery | NEC CORPORATION (JP) | 2016-10-11 | — | — | US | disclosed |
| US-8536205-B2 | Photochromic and electrochromic compounds and synthesis and use thereof | SWITCH MATERIALS INC. (CA) | 2013-09-17 | — | — | US | disclosed |
| US-20130164605-A1 | SECONDARY BATTERY | NEC CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20100190868-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | SWITCH MATERIALS INC. (CA) | 2010-07-29 | — | — | US | disclosed |
| US-20090088448-A1 | Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders | WYETH (US) | 2009-04-02 | — | — | US | disclosed |
| US-7476678-B2 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1888553-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | Switch Materials Inc. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20080027089-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-7273874-B2 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1828203-A2 | RAPAMYCIN DERIVATIVES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Wyeth (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006125317-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | SWITCH MATERIALS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006068905-A2 | RAPAMYCIN DERIVATIVES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135550-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135550-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | MTOR, RPTOR, RICTOR | ALDH1A1 3254/4885TSHR 1065/4885CYP2C9 2858/4885 |
| US-20100190868-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | HCN2, HCN1, SCO2 | ALDH1A1 488/4885TSHR 4023/4885CYP2C9 515/4885 |
| US-20090088448-A1 | Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders | RICTOR, BDNF, NLN | ALDH1A1 2988/4885TSHR 4225/4885CYP2C9 3675/4885 |
| US-20080027089-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | RPTOR, MTOR, RICTOR | ALDH1A1 3946/4885TSHR 1903/4885CYP2C9 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.